Pathogen- and Host-directed Anti-inflammatory Activities of Macrolide Antibiotics

Overview

Journal Mediators Inflamm

Publisher Wiley

Specialties Biochemistry
Pathology

Date 2012 Jul 11

PMID 22778497

Citations 45

Authors

Helen C Steel

Annette J Theron

Riana Cockeran

Ronald Anderson

Charles Feldman

Affiliations

Soon will be listed here.

Abstract

Macrolide antibiotics possess several, beneficial, secondary properties which complement their primary antimicrobial activity. In addition to high levels of tissue penetration, which may counteract seemingly macrolide-resistant bacterial pathogens, these agents also possess anti-inflammatory properties, unrelated to their primary antimicrobial activity. Macrolides target cells of both the innate and adaptive immune systems, as well as structural cells, and are beneficial in controlling harmful inflammatory responses during acute and chronic bacterial infection. These secondary anti-inflammatory activities of macrolides appear to be particularly effective in attenuating neutrophil-mediated inflammation. This, in turn, may contribute to the usefulness of these agents in the treatment of acute and chronic inflammatory disorders of both microbial and nonmicrobial origin, predominantly of the airways. This paper is focused on the various mechanisms of macrolide-mediated anti-inflammatory activity which target both microbial pathogens and the cells of the innate and adaptive immune systems, with emphasis on their clinical relevance.

Citing Articles

Menadione as Antibiotic Adjuvant Against : Mechanism of Action, Efficacy and Safety.

Shehu K, Schneider M, Kraegeloh A Antibiotics (Basel). 2025; 14(2).

PMID: 40001407 PMC: 11851977. DOI: 10.3390/antibiotics14020163.

Antibiotics for the Secondary Prevention of Coronary Heart Disease.

Mansoor M, Hamer O, Walker E, Hill J Br J Card Nurs. 2024; 17(10):1-7.

PMID: 38812658 PMC: 7616032. DOI: 10.12968/bjca.2022.0082.

Augmentation of Therapeutic Efficacy of Extraction of Causative Teeth by Irrigation for Odontogenic Maxillary Sinusitis.

Kato T, Sakagami H In Vivo. 2024; 38(3):1236-1242.

PMID: 38688640 PMC: 11059924. DOI: 10.21873/invivo.13560.

Erythromycin Restores Osteoblast Differentiation and Osteogenesis Suppressed by Lipopolysaccharide.

Tamura H, Maekawa T, Domon H, Sirisereephap K, Isono T, Hirayama S Pharmaceuticals (Basel). 2023; 16(2).

PMID: 37259446 PMC: 9959121. DOI: 10.3390/ph16020303.

Efficacy and safety of macrolides in the treatment of children with bronchiectasis: a meta-analysis.

Song G, Zhang Y, Yu S, Sun M, Zhang B, Peng M Pediatr Res. 2023; 94(5):1600-1608.

PMID: 37237074 DOI: 10.1038/s41390-023-02591-5.

References

Maimon N, Lipton J, Chan C, Marras T . Macrolides in the treatment of bronchiolitis obliterans in allograft recipients. Bone Marrow Transplant. 2009; 44(2):69-73. DOI: 10.1038/bmt.2009.106. View

Morikawa K, Zhang J, Nonaka M, Morikawa S . Modulatory effect of macrolide antibiotics on the Th1- and Th2-type cytokine production. Int J Antimicrob Agents. 2002; 19(1):53-9. DOI: 10.1016/s0924-8579(01)00457-5. View

Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A . Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration. 1991; 58(3-4):145-9. DOI: 10.1159/000195915. View

Cervin A, Wallwork B . Anti-inflammatory effects of macrolide antibiotics in the treatment of chronic rhinosinusitis. Otolaryngol Clin North Am. 2005; 38(6):1339-50. DOI: 10.1016/j.otc.2005.08.002. View

Mandell G . Delivery of antibiotics by phagocytes. Clin Infect Dis. 1994; 19(5):922-5. DOI: 10.1093/clinids/19.5.922. View

Tagaya E, Tamaoki J, Kondo M, Nagai A . Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest. 2002; 122(1):213-8. DOI: 10.1378/chest.122.1.213. View

Majima Y . Clinical implications of the immunomodulatory effects of macrolides on sinusitis. Am J Med. 2004; 117 Suppl 9A:20S-25S. DOI: 10.1016/j.amjmed.2004.07.025. View

Yasutomi M, Ohshima Y, Omata N, Yamada A, Iwasaki H, Urasaki Y . Erythromycin differentially inhibits lipopolysaccharide- or poly(I:C)-induced but not peptidoglycan-induced activation of human monocyte-derived dendritic cells. J Immunol. 2005; 175(12):8069-76. DOI: 10.4049/jimmunol.175.12.8069. View

Southern K, Barker P, Solis-Moya A, Patel L . Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev. 2011; (12):CD002203. DOI: 10.1002/14651858.CD002203.pub3. View

10.

Fukuda Y, Yanagihara K, Higashiyama Y, Miyazaki Y, Hirakata Y, Mukae H . Effects of macrolides on pneumolysin of macrolide-resistant Streptococcus pneumoniae. Eur Respir J. 2006; 27(5):1020-5. DOI: 10.1183/09031936.06.00116805. View

11.

Nakamura H, Fujishima S, Inoue T, Ohkubo Y, Soejima K, Waki Y . Clinical and immunoregulatory effects of roxithromycin therapy for chronic respiratory tract infection. Eur Respir J. 1999; 13(6):1371-9. DOI: 10.1183/09031936.99.13613809. View

12.

Wozniak D, Keyser R . Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest. 2004; 125(2 Suppl):62S-69S. DOI: 10.1378/chest.125.2_suppl.62s. View

13.

Altenburg J, de Graaff C, van der Werf T, Boersma W . Immunomodulatory effects of macrolide antibiotics - part 2: advantages and disadvantages of long-term, low-dose macrolide therapy. Respiration. 2010; 81(1):75-87. DOI: 10.1159/000320320. View

14.

Basyigit I, Yildiz F, Kacar Ozkara S, Yildirim E, Boyaci H, Ilgazli A . The effect of clarithromycin on inflammatory markers in chronic obstructive pulmonary disease: preliminary data. Ann Pharmacother. 2004; 38(9):1400-5. DOI: 10.1345/aph.1D634. View

15.

Tenson T, Lovmar M, Ehrenberg M . The mechanism of action of macrolides, lincosamides and streptogramin B reveals the nascent peptide exit path in the ribosome. J Mol Biol. 2003; 330(5):1005-14. DOI: 10.1016/s0022-2836(03)00662-4. View

16.

Sharma S, Jaffe A, Dixon G . Immunomodulatory effects of macrolide antibiotics in respiratory disease: therapeutic implications for asthma and cystic fibrosis. Paediatr Drugs. 2007; 9(2):107-18. DOI: 10.2165/00148581-200709020-00004. View

17.

Aoki Y, Kao P . Erythromycin inhibits transcriptional activation of NF-kappaB, but not NFAT, through calcineurin-independent signaling in T cells. Antimicrob Agents Chemother. 1999; 43(11):2678-84. PMC: 89542. DOI: 10.1128/AAC.43.11.2678. View

18.

Rubin B, Henke M . Immunomodulatory activity and effectiveness of macrolides in chronic airway disease. Chest. 2004; 125(2 Suppl):70S-78S. DOI: 10.1378/chest.125.2_suppl.70s. View

19.

Verleden G, Dupont L . Azithromycin therapy for patients with bronchiolitis obliterans syndrome after lung transplantation. Transplantation. 2004; 77(9):1465-7. DOI: 10.1097/01.tp.0000122412.80864.43. View

20.

Bratzler D, Ma A, Nsa W . Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project. Clin Infect Dis. 2008; 47 Suppl 3:S193-201. DOI: 10.1086/591404. View